Your browser doesn't support javascript.
loading
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.
Avet-Loiseau, Hervé; Fonseca, Rafael; Siegel, David; Dimopoulos, Meletios A; Spicka, Ivan; Masszi, Tamás; Hájek, Roman; Rosiñol, Laura; Goranova-Marinova, Vesselina; Mihaylov, Georgi; Maisnar, Vladimír; Mateos, Maria-Victoria; Wang, Michael; Niesvizky, Ruben; Oriol, Albert; Jakubowiak, Andrzej; Minarik, Jiri; Palumbo, Antonio; Bensinger, William; Kukreti, Vishal; Ben-Yehuda, Dina; Stewart, A Keith; Obreja, Mihaela; Moreau, Philippe.
Afiliación
  • Avet-Loiseau H; Centre de Recherche en Cancérologie de Toulouse INSERM U1037, Toulouse, France; L'Institut Universitaire du Cancer de Toulouse-Oncopole, Centre Hospitalier Universitaire, Toulouse, France;
  • Fonseca R; Mayo Clinic, Scottsdale, AZ;
  • Siegel D; John Theurer Cancer Center at Hackensack University, Hackensack, NJ;
  • Dimopoulos MA; National and Kapodistrian University of Athens, Athens, Greece;
  • Spicka I; Department of Internal Medicine, University Hospital, Praha, Czech Republic;
  • Masszi T; St. István and St. Laszlo Hospital, Budapest, Hungary;
  • Hájek R; University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic;
  • Rosiñol L; Hospital Clínic de Barcelona, Barcelona, Spain;
  • Goranova-Marinova V; Hematology Clinic University Multiprofile Hospital for Active Treatment "Sv. Georgi" and Medical University, Plovdiv, Bulgaria;
  • Mihaylov G; Queen Joanna University Hospital, Sofia, Bulgaria;
  • Maisnar V; Charles University Faculty Hospital and Faculty of Medicine, Hradec Králové, Czech Republic;
  • Mateos MV; University Hospital of Salamanca/Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain;
  • Wang M; The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Niesvizky R; Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY;
  • Oriol A; Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain;
  • Jakubowiak A; University of Chicago Medical Center, Chicago, IL;
  • Minarik J; Department of Hemato-oncology, University Hospital Olomouc, Olomouc, Czech Republic;
  • Palumbo A; University of Torino, Torino, Italy;
  • Bensinger W; Fred Hutchinson Cancer Research Center, Seattle, WA;
  • Kukreti V; Princess Margaret Cancer Centre, Toronto, ON, Canada;
  • Ben-Yehuda D; Hadassah-Hebrew University Medical Center, Jerusalem, Israel;
  • Stewart AK; Mayo Clinic, Scottsdale, AZ;
  • Obreja M; Onyx Pharmaceuticals Inc., South San Francisco, CA; and.
  • Moreau P; University of Nantes, Nantes, France.
Blood ; 128(9): 1174-80, 2016 09 01.
Article en En | MEDLINE | ID: mdl-27439911
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiple Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Año: 2016 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiple Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Año: 2016 Tipo del documento: Article